Thus, components of the EGFR and PI3K pathways, including the serine/threonine kinase Akt and the MTOR (mechanistic target of rapamycin kinase), are widely considered potential targets to develop new GBM treatments in combination with other therapeutics [6,7]. This evidence concerns the gene MTOR and glioblastoma.